AAP
BCAX

Arax Advisory Partners’s Bicara Therapeutics BCAX Stock Holding History

Arax Advisory Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Buy
63
+55
+688% +$1.23K ﹤0.01% 4829
2026
Q1 		$159 Buy
8
+5
+167% +$86 ﹤0.01% 3569
2025
Q4 		$50 Sell
3
-67
-96% -$1.14K ﹤0.01% 3917
2025
Q3 		$1.1K Buy
70
+11
+19% +$123 ﹤0.01% 3237
2025
Q2 		$549 Buy
+59
New +$703 ﹤0.01% 2923

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's BCAX Position: Q2 2026 in Review

Arax Advisory Partners increased its Bicara Therapeutics (BCAX) stake by 688% in Q2 2026, buying an estimated $1.23K and bringing the position to 63 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #4829.

Arax Advisory Partners first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Arax Advisory Partners held 63 shares of Bicara Therapeutics worth $1.87K as of Q2 2026.
  • Arax Advisory Partners bought 55 Bicara Therapeutics shares in Q2 2026, an estimated $1.23K.
  • Bicara Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4829 holding.
  • Arax Advisory Partners first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.